A/Prof David Anderson

Deputy Director
Centre for Biomedical Research
Burnet Institute

anderson@burnet.edu.au

Licensing opportunities

Burnet spinoff Nanjing BioPoint Diagnostics is interested in novel diagnostics for unmet medical needs especially using lateral flow immunochromatography, with R&D both at Burnet and in Nanjing to help convert promising assays from other formats such as ELISAs
ISAs
EMAIL ENQUIRY >

Contract research opportunities

Development of point of care (lateral flow) diagnostics
tics
EMAIL ENQUIRY >

Other opportunities

Joint venture or license development of diagnostics
tics
EMAIL ENQUIRY >

Research Activities

Our major activities are in translational research in diagnostics:
(1) the development of rapid, point-of-care and/or laboratory-based assays for the diagnosis and management of infectious diseases including HIV, syphilis, hepatitis and liver disease, gut leakage and sepsis;
(2) commercial development of diagnostics through Burnet's spinoff company, Nanjing BioPoint Diagnostics (PR China), with ISO13485 (2016) certified manufacturing facilities in China, allowing production for registration and sale (eg CE mark for EU and other markets).

Techniques/Expertise

Assay development, validation and pilot manufacture for ELISA and rapid, point of care tests (including contract services)

Collaborations

Suzanne Crowe
Brendan Crabb
Greg Tannock, Burnet Institute
Alan Landay, Rush University, Chicago
Tom Denny, Duke University, Durham
Bill Heath, Axxin Ltd
A/Prof Rosemary Ffrench
Jack Richards
Mary Garcia
Roy Hall
Jody Peters

Other Lab Members

Mary Garcia
Huy Van
Fan Li

Research Images

Other members with similar research interests

prev next

Dr Rob Center

Disease Elimination Program Burnet Institute SEE FULL PROFILE >

Dr Darren Creek

Monash Institute of Pharmaceutical Sciences Monash University SEE FULL PROFILE >

Miss Michelle Clark

Infection and Immunity Division Walter and Eliza Hall Institute of Medical Research SEE FULL PROFILE >